UK's cost-ef­fec­tive­ness gate­keep­er wants to pro­vide faster ac­cess to more new drugs

The UK’s ar­biter of cost-ef­fec­tive­ness de­ci­sions for new drugs, known as the Na­tion­al In­sti­tute for Health and Care Ex­cel­lence or NICE, is plot­ting a ma­jor makeover as the gate­keep­er has long been fa­mous for re­ject­ing and re­strict­ing ac­cess to cost­ly new med­i­cines.

Now, how­ev­er, NICE says it wants to change its ways “to pro­vide faster and fair­er ac­cess” to new drugs and de­vices to the Na­tion­al Health Ser­vice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER